Colorectal Cancer Clinical Trials

Showing 661-680 of 1,434 trials

Late Organ Specific Adverse Effects hiPec or pElvic eXenteration

NCT04970316

The purpose of this study is to describe type and extent of organ specific late adverse effects in patients undergoing surgery for colorectal cancer with peritoneal metastases and after surgery for colorectal cancer with involvement of the urinary bladder.

Colorectal Cancer

University of Aarhus225 participantsStarted Jan 2021

Aarhus, Denmark • Solna, Stockholm County, Sweden • Malmo, Sweden

UNKNOWNPHASE2

The Efficacy and Safety of Fluzoparib Plus Irinotecan as Second-line Treatment in Patients With Homologous Recombination Deficiency (HRD) Metastatic Colorectal Cancer.

NCT05732129

Preclinical data support the investigation of PARP inhibitors in other neoplasms exhibiting homologous recombination deficiency (HRD) as monotherapy as well as in combination with chemotherapy. However，in colorectal cancer (CRC), the role of HRD alterations is mostly unknown. This study aims to explore the the Efficacy and Safety of Fluzoparib combined with Irinotecan in the Second-line treatment of HRD alterations metastatic colorectal cancer.

Homologous Recombination Deficiency Alterations Metastatic Colorectal Cancer

Fudan University29 participantsStarted Mar 2023

Shanghai, Shanghai Municipality, China

RECRUITINGPHASE2

Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal Cancer

NCT05725200

The purpose of the study is to investigate the effect and side effects of personalized cancer treatment in patients with metastatic colorectal cancer (bowel cancer). All patients included must have metastatic bowel cancer and receive or have received at least two lines of standard chemotherapy. The cancer must not be available for surgery with curative intent.

Metastatic Colorectal Cancer

Oslo University Hospital40 participantsStarted Sep 2022

Oslo, Norway

Late Organ Specific Adverse Effects hiPec or pElvic eXenteration

The Efficacy and Safety of Fluzoparib Plus Irinotecan as Second-line Treatment in Patients With Homologous Recombination Deficiency (HRD) Metastatic Colorectal Cancer.

Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal Cancer

Related Searches

Multi-points and Full-thickness Biopsy in the Diagnosis of cCR After Neoadjuvant Therapy for Rectal Cancer

Efficacy of VIC Regimen in BRAF Mutant Metastatic Colorectal Cancer

Re-challenge of Anti-EGFR for Patients With RAS/BRAF Wild-type Metastatic CRC

Quad Resection (Hot Snare vs Cold Snare vs Hot EMR vs Cold EMR)

A Study of Systemic Chemotherapy With CPT-11 Plus HAI (FUDR+L-OHP) in Patients With Initially Unresectable CRCLM

PET/MR for Rectal Cancer Treatment Monitoring and Surveillance

Peptide-based Immunization for Colon- and and Pancreas-carcinoma

Evaluation of the Safety and the Tolerability of Durvalumab Plus Tremelimumab Combined With FOLFOX in mCRC

Early Blocking Strategy for Metachronous Liver Metastasis of Colorectal Cancer Based on Pre-hepatic CTC Detection

Pancreas Resection for Colorectal Metastasis: Retrospective Study

Explore Biomarkers Associated With Prognosis of Recurrent and Metastatic CRC After Surgery by Multi-omics Methods

A Multi Center Study Comparing the Efficacy of CAD EYE and the Standard of Care (White Light )

Lateral Nodal Recurrence in Rectal Cancer

Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S

Predictive Value of Drug Sensitivity Testing Tumorspheres From Patients With Metastatic Colorectal Cancer

A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat

Targeted Delivery of Chemotherapy With Ultrasound and Microbublles